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Cyclin-dependent kinases (CDKs) require the binding to a regulatory subunit to acquire 
enzymatic activity, and cyclins are the canonical CDK activators. However, there are specific 
situations in which CDKs can be activated by non-cyclin proteins that are less characterized. 
This review focuses on the family of RINGO/Speedy proteins, which have no sequence amino 
acid homology to cyclins but can bind to and activate CDK1 and CDK2. Interestingly, 
RINGO/Speedy proteins can activate CDKs under conditions in which CDK-cyclin 
complexes would not be active, and there is evidence that RINGO/Speedy-activated CDKs 
can phosphorylate different sites than the cyclin-activated CDKs. RINGO/Speedy proteins 
were originally described in Xenopus oocytes, but their roles in mammalian cells have also 
been addressed. We will summarize the properties of RINGO/Speedy proteins and how they 
trigger CDK activation, and discuss recent studies that characterized their physiological 
functions. In particular, studies using genetically modified mice have shown that RingoA, 
also known as Spy1, plays a key role in meiosis regulation. Emerging evidence also suggests 





The periodic activation of so-called cyclin-dependent kinases (CDKs) plays a key role in cell 
cycle progression. The activation of these kinases is controlled by their association with 
regulatory subunits, and also by phosphorylation. The association with a cyclin subunit leads 
to partial CDK activation. Full kinase activation requires the phosphorylation of a Thr on the 
T-loop (Thr161 in CDK1 and Thr160 in CDK2) as well as the removal of the inhibitory 
phosphorylations Thr14 and Tyr15. CDK activity can be further regulated by the binding of 
CDK inhibitors of the INK4 and Cip/Kip families such as p21Cip1 and p27Kip1 [1]. The 
structures, regulatory mechanisms and functions of CDKs have been extensively reviewed [2, 
3]. The roles and regulation of cyclins are the subjects of several reviews in this issue. 
Although cyclins are universal CDK activators, there are cases in which CDKs can be 
activated by proteins that do not belong to the cyclin family. CDK5 is one of the best-known 
examples, as this kinase can be activated by the proteins p35, p39 or p25. CDK5 has 
important roles in post-mitotic neuronal cells and has been implicated in neurodegeneration 
[4]. Growing evidence also implicates CDK5 and its activators in cancer [5, 6].  
This review focuses on the cyclin-like CDK activators of the RINGO/Speedy family. 
These proteins were discovered in Xenopus by two independent screenings. One was an 
expression-cloning screening aimed to find proteins that upon overexpression in G2-arrested 
Xenopus oocytes were able to trigger M phase entry, the initial stage of the meiotic 
maturation, and named them RINGO (Rapid INducer of G2/M progression in Oocytes) [7]. 
The other screening searched for Xenopus genes that were able to confer resistance to UV and 
g-radiation when overexpressed in a Rad1-deficient mutant of the yeast S. pombe, and named 
them Speedy [8]. The role of Xenopus RINGO/Speedy (XRINGO) in oocyte maturation has 
been extensively studied, and is reviewed below.  
Mammalian genes with similarity to XRINGO have been also identified. The first 
human XRINGO homolog was named Spy1 [9], which is also known as Ringo3, SpeedyA or 
RingoA, and here it is referred to as RingoA/Spy1. Other mammalian homologs of XRINGO 
were named RingoC (Ringo2) and RingoE (Ringo1) in human, and RingoB (Ringo4) and 
RingoD (Ringo5) in mouse [10]. A number of variants of this protein family in different 
species and their phylogenetic relationship have been reported [11]. Of note, RINGO/Speedy 
family proteins are notably different between human and mouse, with RingoA/Spy1 being the 
most conserved across species [10, 11].  
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The initial characterization showed that XRINGO was able to bind to and increase the kinase 
activity of both CDK1 and CDK2 [7]. Similar results were later reported for mammalian 
RingoA/Spy1, RingoB, RingoC and RingoE [9, 12, 13]. Intriguingly, overexpression 
experiments in Xenopus oocytes have shown that RingoE but not RingoA/Spy1 or RingoC, 
can also bind to CDK5 [13]. The RINGO/Speedy proteins share a conserved central region of 
approximately 100 residues referred to as the RINGO or S/R box, which is required for CDK 
binding [12, 13]. 
Removing the N-terminal and C-terminal regions of XRINGO does not affect the 
ability of the protein to induce Xenopus oocyte maturation and CDK2 activation in vitro [13], 
but the C-terminal region of RingoA/Spy1 might contribute to CDK activation [12]. In 
addition, the N-terminal domain of RingoA/Spy1 seems to destabilize the protein, as removal 
of this region enhances RingoA/Spy1 expression in transfected HEK293 cells [12]. The 
RINGO/Speedy proteins have no similarity in amino acid sequence with cyclins, however, 
recent structural studies on RingoA/Spy1 have shown that the RINGO box adopts a cyclin-
box fold (CBF) that binds CDK2 in the same position as the N-terminal CBF of CyclinA. 
Moreover, the secondary structural elements of the RINGO box at the CDK PSTAIRE 
interphase align with CyclinA [14]. The largest interface between RingoA/Spy1 and CDK2 
comprises the PSTAIRE region of CDK2 and the helixes a3 and a5 of RingoA/Spy1. These 
observations agree with an earlier mutagenic analysis that identified key residues in the 
PSTAIRE region of CDK2 and in the a3 helix of XRINGO and RingoA/Spy1, which were 
required for binding of the two proteins [13, 15].  
In vitro studies using purified recombinant proteins and injections into Xenopus 
oocytes showed that XRINGO is able to activate CDK1 and CDK2 independently of T-loop 
phosphorylation [16] (Figure 1). This was a surprising observation, considering that the 
kinase activity of cyclin-bound CDK1 and CDK2 strongly increases upon phosphorylation on 
the T-loop. The biochemical results have been confirmed by recently determined crystal 
structures showing that the non-phosphorylated form of CDK2 bound to RingoA/Spy1 adopts 
a conformation similar to the T-loop phosphorylated CDK2 bound to CyclinA [17]. Thus, 
upon RingoA/Spy1 binding, the PSTAIRE region and the T-loop of CDK2 adopt a 
conformation associated with the active kinase, explaining why RingoA/Spy1 binding alone 
suffices to activate CDK2 regardless of the T loop phosphorylation. Mutational analysis 
showed that among the RingoA/Spy1 residues that interact with the CDK2 T-loop, Asp97 and 
Glu135 are critical for kinase activation [14]. Interestingly, it was also shown that the Wee1 
family kinase Myt1 is less efficient at inhibiting CDK-XRINGO than CDK-cyclin complexes 
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[16], suggesting that CDK-RINGO complexes are less sensitive to the inhibition mediated by 
the phosphorylation on Thr14 and/or Tyr15 than CDK-cyclin complexes. It has been also 
reported that CDK2 activated by RINGO/Speedy proteins has reduced sensitivity to p21Cip1 
and p27Kip1. These CDK inhibitors bind to the cyclin CBF through the MRAIL region, which 
RINGO/Speedy proteins lack, providing an explanation for the weaker binding and poorer 
inhibition observed in CDK2-RINGO compared with CDK2-CyclinA [14, 16]. Taken 
together, the ability of RINGO/Speedy proteins to activate CDK1 and CDK2 regardless of the 
activating T-loop phosphorylation and with less sensitivity to Myt1 or CDK inhibitors 
suggests that CDK-RINGO complexes might play important roles in specific situations when 
CDK-cyclin complexes are inhibited (Fig. 1).  
In addition to enable the activation of CDKs under particular conditions, it is 
conceivable that RINGO/Speedy proteins might also affect CDK substrate specificity. This 
was first addressed in studies using peptide libraries, which concluded that RingoA/Spy1-
activated CDK2 has a less strict preference for Lys at +3 position of the phospho-acceptor site 
compared with CDK2-CyclinA [18]. Further work using Myt1 as a substrate provided 
evidence that RINGO/Speedy proteins can lead CDKs to phosphorylate different sites than 
the cyclins [19]. In vitro experiments showed that XRINGO-bound CDK1 or CDK2 are able 
to phosphorylate three residues at the C-terminal regulatory domain of Myt1, which promote 
the inhibition of Myt1 kinase activity, but these residues are poorly phosphorylated by CDK1- 
or CDK2-cyclin complexes. Interestingly, evidence was presented that the RNL sequence of 
Myt1, which is required for binding to CyclinB, was not required for Myt1 phosphorylation 
by XRINGO-activated CDKs. This suggests that XRINGO and cyclin bind to different 
regions of Myt1, which may account for the different sites phosphorylated by the two CDK 
complexes [19]. The three sites identified are likely phosphorylated during the meiotic 
maturation of Xenopus oocytes and can prime Myt1 for the binding to the kinase p90Rsk1, 
which further phosphorylates Myt1 leading to its complete inhibition required for the full 
activation of CDK1-CyclinB complexes and the G2/M progression [20]. Therefore, CDK-
RINGO complexes may have different substrate specificity, in addition to being potentially 
active under conditions in which CDK-cyclin complexes are inactive, such as in G2 arrested 
Xenopus oocytes. 
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RingoA/Spy1 is the most studied mammalian RINGO/Speedy protein.	Human RingoA/Spy1 
mRNA was shown to be expressed in G1/S phase of the cell cycle in HEK293 cells [9]. 
Further work in U20S cells detected RingoA/Spy1	mRNA expression in all stages of the cell 
cycle in an oscillating pattern, peaking in M phase and reaching the lowest levels in mid-late 
G1, very similar to the expression pattern of CyclinA2 [21]. Moreover, myc-RingoA/Spy1	
overexpressed in U20S cells was found to accumulate periodically, reaching the highest levels 
in the G1 phase. The overexpressed myc-RingoA/Spy1	protein was also phosphorylated in 
mitosis [21]. 
RingoA/Spy1 protein overexpressed in U2OS cells was very unstable, and was found 
to bind to the E3 ubiquitin ligase Skp2, which triggered its degradation by the proteasome 
[21]. NEDD4 is another ubiquitin ligase that was found to bind to RingoA/Spy1 and to target 
it for degradation in HEK293 cells [22]. Interestingly, the expression of a stabilized form of 
RingoA/Spy1 fused to GFP resulted in impaired cell cycle progression, with cells having 
abnormal chromatin condensation and morphology. These cells have a similar phenotype as 
those expressing a stable form of CyclinB that prevents mitotic exit, which has been called the 
“reversal of mitosis exit” [23]. This RingoA/Spy1 phenotype is CDK dependent, as it was not 
observed upon expression of a GFP-RingoA/Spy1 mutant unable to bind to CDK [21]. The 
observation that RingoA/Spy1 overexpression interferes with mitotic progression in somatic 
cells suggests that degradation of this protein might be required for the completion of somatic 
mitosis. Previous work showing that XRINGO induces cleavage arrest upon injection into the 
blastomere of two-cell mouse embryos further supports that XRINGO/Speedy proteins 
expressed out of context may have cytostatic activity [24]. 
RingoA/Spy1 has been proposed to control the G1/S transition in human cancer cells, 
based on the observations that RingoA/Spy1-overexpressing HEK293 cells showed a reduced 
G1 phase length, whereas treatment with RingoA/Spy1 siRNA led to an increase in G1 phase 
and reduction in G2/M phases [9]. The ability of human RingoA/Spy1 to interact with p27Kip1 
might explain the observed changes in G1. Consistent with this idea, RingoA/Spy1 
overexpression was shown to overcome the p27Kip1-induced G1 arrest in HEK293 cells [25], 
which correlated with CDK2-mediated phosphorylation of p27Kip1 on Thr187 [26]. More 
recently, the direct binding of RingoA/Spy1 has been reported to destabilize p27Kip1, whereas 
RingoA/Spy1 binding to CDK2 does not seem to affect p27Kip1 stability, suggesting that 
RingoA/Spy1 might regulate p27Kip1 stability independently of Thr187 phosphorylation [27]. 
These observations are intriguing considering that cyclin-bound CDK2 is well-known to 
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phosphorylate p27Kip1 on Thr187 and induce its degradation [28]. It is therefore unclear how 
RingoA/Spy1 can trigger p27Kip1 degradation independently of Thr187 phosphorylation.  
RINGO/Speedy proteins have been proposed to have a role in the DNA damage 
response. First, XRINGO overexpression in Rad1-deficient S. pombe was found to confer 
resistance to UV [8]. Subsequently, the same group published several reports supporting that 
RingoA/Spy1 may allow to bypass DNA damage checkpoint activation in mammalian cells. 
Thus, RingoA/Spy1 overexpression was reported to increase the survival of U2OS cells 
treated with genotoxic drugs [29], and the RingoA/Spy1-overexpressing U2OS cells showed 
reduced levels of phospho-Chk1 and phospho-RPA, as well as reduced sensitivity to UV-
induced apoptosis [30]. The pro-survival role of RingoA/Spy1 in response to UV was 
proposed to depend on the expression of p53 and p21Cip1, and siRNA-mediated knockdown of 
RingoA/Spy1 was described to increase gH2AX foci formation and Chk1 phosphorylation in 
U20S cells [31]. Another study has reported that RingoA/Spy1 expression improves the 
viability of neuronal NSC34 cells overexpressing the superoxide dismutase (SOD1) mutant 
G93A, which have an activated DNA damage response [32]. 
Besides RingoA/Spy1, there is evidence implicating other mammalian 
RINGO/Speedy family members in the regulation of various cell cycle steps. For example, 
siRNA-mediated downregulation of RingoC in HEK293 cells resulted in longer G2 phase, 
whereas the overexpression of RingoC led to faster progression through late S and G2 phases 
and override of the G2 DNA damage checkpoint [33]. Another study using several human 
cancer cell lines has shown that RingoC downregulation leads to premature mitosis exit and 
chromosome alignment problems, with decreased recruitment of spindle assembly checkpoint 
components [34]. RingoC was shown to associate with Aurora B, but did not seem to control 
its kinase activity based on CENPA and H3 phosphorylation, although Thr232 
phosphorylated AuroraB was found to miss-localize in prometaphase upon RingoC 
downregulation [34]. RingoE has also been linked to cell cycle regulation. Surprisingly, 
unlike other RINGO/Speedy proteins, RingoE was found to inhibit progesterone-induced 
Xenopus oocyte maturation, probably by sequestering CDK1 [15]. Although RingoE can 
activate CDK1 in vitro and in Xenopus oocytes, CDK1-RingoE phosphorylates Myt1, a key 
negative regulator of oocyte maturation, with reduced efficiency compared with CDK1-
RingoA/Spy1. These results suggest that different RINGO/Speedy proteins could determine 
the substrate preferences of CDKs and potentially regulate different biological functions. In 
agreement with the observations in Xenopus oocytes, overexpression of RingoE has been 
reported to inhibit the proliferation of U20S cells, reducing the amount of cells in G1 while 
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enhancing the cells in G2/M [15]. Of note, as for RingoA/Spy1, RingoC and RingoE 
overexpressed in Xenopus oocytes have been also reported to interact with p27Kip1 [13], 
although it remains to be determined whether this has any physiological significance. 
 
4. Meiotic functions  
There is evidence supporting that XRINGO is both necessary and sufficient for triggering the 
G2/M transition in Xenopus oocytes. XRINGO was identified for its ability to induce G2 
arrested Xenopus oocytes to enter meiotic maturation in the absence of progesterone 
stimulation [7], suggesting a role of this protein in meiosis regulation. Further work showed 
that endogenous XRINGO protein accumulates transiently during meiosis I in progesterone-
treated oocytes and then is downregulated. Two proteasome-mediated mechanisms have been 
proposed to contribute to the regulation of XRINGO expression. One leads to partial 
processing generating a C-terminally truncated form, which may contribute to the oocyte G2 
arrest. This involves the ubiquitin ligase SCFβTrCP and requires XRINGO phosphorylation by 
protein kinase A and glycogen synthase kinase-3β. On the other hand, XRINGO degradation 
after meiosis I is mediated by the ubiquitin ligase Siah-2 and requires phosphorylation on 
Ser243 [35]. As mentioned above, the ability of CDK-XRINGO to phosphorylate Myt1 may 
account for its ability to induce Xenopus oocyte maturation. Myt1 can phosphorylate CDK1 
on Thr14 and Tyr15, resulting in kinase inhibition, and is believed to play an important role in 
keeping the preformed CDK1-CyclinB complexes inhibited in the G2 arrested Xenopus 
oocytes [36]. Dephosphorylation of these two residues by Cdc25 phosphatases leads to 
CDK1-CyclinB complex activation [37, 38]. In late G2 phase, there is a switch in the balance 
between Myt1 and Cdc25, which leads to the dephosphorylation of CDK1 bound to Cyclin B 
and activation of the complex, allowing the oocyte to enter into meiosis I. CDK-XRINGO can 
phosphorylate three Ser on the C-terminal non-catalytic domain of Myt1, inhibiting its kinase 
activity, and these sites are poorly phosphorylated by CDK-cyclin complexes. Taken together, 
these results support that XRINGO plays an important triggering role at the G2/M transition 
of Xenopus oocytes by inducing Myt1 inhibition [19, 20]. 
The role of RINGO/Speedy proteins in mammalian oocytes has also been investigated. 
The injection of a porcine RINGO/Speedy homolog has been shown to accelerate the 
maturation of porcine oocytes [39], and mammalian RINGO/Speedy proteins can induce 
Xenopus oocyte maturation, albeit with less efficacy than XRINGO [9, 12, 13]. Moreover, the 
injection of XRINGO mRNA suffices to induce germinal vesicle breakdown (GVBD) and 
first polar body extrusion in mouse oocytes [24]. These findings suggest that RINGO/Speedy 
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proteins may have a role in the maturation of mammalian oocytes. However, mice bearing 
RingoA/Spy1lox/lox alleles and Zp3-Cre, which is expressed in postnatal oocytes, seem to be 
affected neither in oocyte maturation nor in female fertility [40]. It is therefore possible that 
endogenous RingoA/Spy1 might not be required for oocyte maturation in mice. However, it 
remains to be confirmed that RingoA/Spy1 expression is indeed abolished in the oocytes from 
RingoA/Spy1lox/lox Zp3-Cre mice.  
Independently of whether RingoA/Spy1 might be involved in mammalian oocyte 
maturation, recent studies using genetically modified mice have demonstrated a key role for 
this protein in meiosis regulation. Thus, RingoA/Spy1-deficient mice are sterile [40, 41], and 
phenocopy the defects of CDK2-deficient mice [42]. This observation, together with the fact 
that RingoA/Spy1 can interact with and activate CDK2, suggests that RingoA/Spy1 is an 
essential activator of this kinase during the meiotic process. Mice expressing a CDK2 mutant 
that is deficient in catalytic activity show similar phenotypes as the CDK2 knockout and 
RingoA/Spy1 knockout mice, suggesting that the kinase activity of CDK2 is essential in the 
process [43]. RingoA/Spy1 was found to localize to the telomeric regions of spermatocytes, 
overlapping with TRF1 from leptotene to pachytene. This telomeric location is very similar to 
the one described for CDK2. RingoA/Spy1 is detectable in telomeres located at the nuclear 
envelope in pre-leptotene, co-localizes with CDK2 in telomeres during leptotene and 
zygotene, and then the signal is reduced as cells enter diplotene (Fig. 2A). Moreover, 
RingoA/Spy1 and CDK2 co-localize along the asynapsed axial elements of the sex 
chromosomes in about 60% of their surface. The interaction between endogenous 
RingoA/Spy1 and CDK2 in testis was confirmed by immunoprecipitation [40, 41]. In testis, 
RingoA/Spy1 protein expression starts from postnatal day 12 (P12), and in female germ cells, 
mRNA expression starts around 14.5 days post coitum (dpc), when they enter meiosis, and 
decreases at 18.5-19.5 dpc, being dramatically reduced in adult ovaries [40] (Fig. 2A).  
Studies in spermatocytes showed that RingoA/Spy1 is essential for the tethering of 
telomeres to the nuclear envelope during meiotic prophase. Spermatocytes from RingoA/Spy1 
knockout mice are arrested in mid-pachytene of meiosis I, display non-homologous pairing, 
telomere fusions, and inefficient double-strand break repair, and also lacked sex-body 
formation (Fig. 2B). Interestingly, CDK2 is absent from telomeres of RingoA/Spy1 knockout 
spermatocytes at the pachytene-like stage, suggesting that RingoA/Spy1 is necessary for the 
recruitment of CDK2 to telomeres [40, 41]. This was further supported by overexpression 
experiments showing that a CDK2 mutant deficient in RingoA/Spy1 binding was unable to 
locate to telomeres in spermatocytes. Moreover, it has been reported that TRF1 directly 
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interacts with RingoA/Spy1 whereas CDK2 interacts with TRF1 through RingoA/Spy1 [44]. 
Therefore, RingoA/Spy1 has been proposed to function as a scaffold that mediates CDK2 
recruitment to telomeres. 
RingoA/Spy1 deficient spermatocytes also lack telomeric Sun1, a protein essential for 
telomere tethering to the nuclear envelope. CDK2-RingoA/Spy1 can directly phosphorylate 
Sun1 in vitro, and Sun1 phosphorylation could therefore account for most of the phenotypes 
observed in RingoA/Spy1 KO spermatocytes. However, it seems unlikely that Sun1 
phosphorylation could explain the observed telomere fusion phenotype [41]. 
According to the serious meiotic defects observed, both male and female 
RingoA/Spy1 knockout mice are sterile. RingoA/Spy1 knockout mice show normal testes at 
post-natal day 7 (P7) but from two months of age their testes are atrophied, hypoplastic and 
lack round and elongated spermatids. The histological analysis showed abnormal epithelium, 
narrower seminiferous tubules and lack of post-meiotic cells. In females, there is an almost 
total loss of oocytes from P5 onwards, and ovaries are also atrophic and mainly composed of 
interstitial and stromal cells [40, 41]. 
In general, RINGO/Speedy family members tend to be highly expressed in testes but 
very little is known on whether other RINGO/Speedy proteins besides RingoA/Spy1 are 
implicated in meiosis. We have generated RingoB knockout mice and found that they are 
fertile (L Gonzalez and A Nebreda, unpublished observations) indicating that RingoB does 
not play an essential role in meiosis regulation.  
 
5. A potential role in cancer 
The ability of RINGO/Speedy proteins to activate CDKs under conditions that are not 
favorable for CDK-cyclin activation, suggest that these proteins may potentially control cycle 
progression in special situations, such as in cancer. A number of studies have reported 
correlations between RingoA/Spy1 overexpression and bad prognosis in human tumors, 
including hepatocellular carcinoma [45], glioma [46], non-Hodgkin’s lymphoma [47], ovarian 
[48], and colorectal [49]. However, these results should be taken with caution, as they are 
based on immunohistochemistry analysis and no controls were provided to demonstrate that 
the staining really corresponds to RingoA/Spy1 expression.  
The possible role of RingoA/Spy1 in breast cancer has been documented in several 
studies. It has been reported that RingoA/Spy1 expression is upregulated in breast cancer 
tissue microarrays (TMAs) and several breast cancer cell lines, and both MDA-MB-231 and 
MCF-7 cells shown decreased proliferation upon siRNA-induced knockdown of 
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RingoA/Spy1 [50]. RingoA/Spy1 expression has also been described to change during 
mammary gland development. Thus, RingoA/Spy1 mRNA and protein levels have been 
detected at higher levels in virgin mammary glands and during early pregnancy to be then 
dramatically reduced in lactation. The same study reported that HC11 mammary epithelial 
cells stably overexpressing RingoA/Spy1 were able to refill the cleared mammary fat pad of 
syngeneic mice at a faster rate, showed increased ductal branching and produced enhanced 
mammary tumorigenesis compared with parental HC11 cells [51]. Using the same fat pad 
transplantation model, HC11 cells expressing an N-terminally truncated (more stable) 
RingoA/Spy1 mutant were shown to form tumors faster [50], whereas cells expressing 
RingoA/Spy1 mutants deficient in either p27Kip1 or CDK2 binding formed tumors more 
slowly [52]. The activation of ERa has been proposed to induce RingoA/Spy1 upregulation in 
MCF-7 cells, which might in turn control the ERK1/2 mediated phosphorylation of ERa on 
Ser118, and sensitivity to tamoxifen tested by injection of RingoA/Spy1 overexpressing 
MCF-7 cells in zebrafish [53]. RingoA/Spy1 levels have been also proposed to be controlled 
by p53 in HC11, MDA-MB-231 and HEK293 cells in which RingoA/Spy1 is overexpressed, 
but there is no evidence that the endogenous protein follows the same dynamics [54]. It 
should be noted that the quality of the loading controls in some of these experiments is not 
optimal, and further work would be needed to confirm the statements. Moreover, cMyc 
overexpression in mouse embryonic fibroblasts has been reported to induce the upregulation 
of RingoA/Spy1 protein and mRNA [51]. However, other studies have not identified 
RingoA/Spy1 among the cMyc-regulated genes [55]. 
A recent study has reported that transgenic mice expressing MMTV-RingoA/Spy1 
show enhanced hepatic cell proliferation and increased incidence of liver tumors, which led 
the authors to propose that RingoA/Spy1 may promote susceptibility to non-cirrhotic 
hepatocellular carcinoma [56]. Moreover, studies based on the use of a single siRNA 
concluded that RingoA/Spy1 knockdown reduces cell proliferation and increases the number 
of cells in G0/G1 phases in the ovarian cancer cell line SKOV-3 [48] and the leukemia cell 
line Jurkat [47]. 
RingoA/Spy1 has been also proposed to play a role in glioma. It has been reported that 
higher levels of RingoA/Spy1 (SPDYA gene) amplification in glioma samples correlated with 
reduced patient survival based on the evaluation of data from the Rembrandt NCI database 
[57]. The same study concluded that RingoA/Spy1 protein is overexpressed in some human 
glioma tumors, based on the analysis of a small number of samples. However, we have not 
been able to find correlations between SPDYA mRNA expression levels and the prognosis of 
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glioma patients using other tumor databases, nor evidence that RingoA/Spy1 is overexpressed 
in glioma tumors by immunohistochemistry analysis (unpublished observations). Experiments 
using human cancer cell lines in culture support a potential role of RingoA/Spy1 in glioma 
[57]. Thus, shRNA-mediated downregulation of RingoA/Spy1 was reported to reduce the 
proliferation of glioma cells. Moreover, RingoA/Spy1 mRNA expression was found enriched 
in CD133+ cells and was proposed to regulate the stemness properties. RingoA/Spy1 
overexpression was also shown to enhance clonality and viability of glioma cells, while 
reducing their capacity to differentiate, based on the qRT-PCR analysis of markers. Finally, 
RingoA/Spy1 knockout human brain cancer cells were reported to divide in a more 
asymmetric manner, therefore suggesting a role for RingoA/Spy1 in the self-renewal potential 
of brain tumor cells with stemness properties [57]. Differentiated neuroblastoma SH-SY5Y 
cells have been also reported to have decreased RingoA/Spy1 protein levels, and 
RingoA/Spy1 overexpression resulted in increased self-renewal in neurosphere assays and 
delayed cell differentiation [58]. Another study has proposed that RingoA/Spy1 associates 
with CLIPR-59, when both proteins were overexpressed in HEK-293-T cells, which might in 
turn reduce the association of CLIPR-59 with the de-ubiquitinating enzyme CYLD and affect 
the de-ubiquitination of RIP1 [59]. It is unclear how in this study RingoA/Spy1 co-localizes 
with CLIPR-59 in the cytoplasm, since previous work has shown that overexpressed 
RingoA/Spy1 localizes in the nucleus [9, 21].  
 
6. Conclusions and perspectives 
There is good evidence that the binding of RINGO/Speedy proteins suffices to increase the 
kinase activity of CDK1 and CDK2, as demonstrated by biochemical experiments using 
purified proteins. Importantly, recent structural studies have provided the molecular basis for 
the activation of CDK2 by RingoA/Spy1 interaction. Moreover, it has been demonstrated that 
T-loop phosphorylation of the CDK is not necessary for its activation by RINGO/Speedy 
proteins, and that RINGO/Speedy-activated CDKs are less sensitive to CKIs. Altogether, 
these observations indicate that CDK-RINGO/Speedy complexes can be active under 
conditions where CDK-cyclin complexes are likely to have low activity, and therefore can 
potentially perform different functions. In addition, XRINGO-activated CDKs can 
phosphorylate different sites in the kinase Myt1 than the same CDKs activated by cyclins. 
This can be mechanistically explained because RINGO/Speedy binds to a different region of 
Myt1 than cyclins and therefore both regulatory subunits position the CDK differently. 
Whereas these results provide a clear example of how CDKs can phosphorylate different sites 
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when activated by RINGO/Speedy or cyclins, we are not aware of any evidence that CDK-
RINGO/ Speedy complexes can phosphorylate new substrates not targeted by CDK-cyclins. 
At the physiological level, there is evidence that XRINGO regulates the meiotic 
maturation of Xenopus oocytes. In mammals, experiments using genetically modified mice 
have demonstrated that RingoA/Spy1 is essential for the prophase of meiosis I. Accordingly, 
RingoA/Spy1 knockout mice both males and females are sterile. However, these mice appear 
to be otherwise normal, which agrees with RingoA/Spy1 being mainly expressed in testis and 
embryonic ovary, with very low or absent expression in other tissues. Altogether the available 
data suggest that RingoA/Spy1 is crucial for meiosis in mammals but seems to be dispensable 
for the mitotic cell cycle in somatic tissues. Nevertheless, it remains to be clarified whether 
RingoA/Spy1 could play a role in particular cell types or situations in which the cell cycle 
might be differently regulated. 
There are also several reports suggesting a role for RingoA/Spy1 in cancer, which usually 
link RingoA/Spy1 overexpression with enhanced tumorigenesis. The majority of these studies 
were performed in established cancer cell lines and, although some observations are 
potentially interesting, they are often based on overexpression experiments. In many cases, 
there is a lack of support from loss-of function experiments or evidence that the endogenous 
RingoA/Spy1 protein behaves in a similar way, and some of the data published is of 
borderline quality. Therefore, conclusions should be considered with caution. 
In our experience, detection of the endogenous RingoA/Spy1 protein is technically 
challenging, and many studies that report RingoA/Spy1 expression in different tumor types, 
lack controls to prove the specificity of the antibodies used. Moreover, although several 
studies point to the overexpression of RingoA/Spy1 mRNA in tumors, this correlation is not 
detected in publicly available databases of human tumor samples, and RingoA/Spy1 seems to 
be frequently expressed at very low levels in tumors (L Gonzalez and A Nebreda, 
unpublished observations). Finally, there are no studies analyzing the effect of the 
endogenous RingoA/Spy1 protein depletion using genetic models, except for the two recently 
published papers showing that mice lacking this protein are sterile. 
In summary, RINGO/Speedy proteins are atypical activators of CDK1 and CDK2, which 
play key roles in meiosis. Further work will be needed to establish their role in particular 
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Fig. 1. Mechanisms that regulate the function of RINGO/Speedy proteins. Binding of 
RINGO/Speedy proteins to CDK1 and CDK2 suffices to induce activation of these kinases 
under conditions in which CDK-cyclin complexes would not be active. In particular, CDK-
RINGO/Speedy complexes are equally active regardless of the CDK phosphorylation on the 
T-loop, are less affected by the p21Cip1 and p27Kip1 CDK inhibitors, and are able to 
phosphorylate and inhibit the CDK negative regulators p27Kip1 and Myt1. The E3 ubiquitin 
ligases Skp2 and NEDD4 can interact with and induce the degradation of the overexpressed 
RingoA/Spy1, while SCFbTrcP and Siah-2 regulate XRINGO processing and degradation, 
	 18	
respectively. Gray symbols indicate whether the links have been made using mammalian 






















Fig. 2. RingoA/Spy1 is essential for meiotic prophase I. (A) RingoA/Spy1 is expressed in 
male gonads from postnatal day 12 (P12) onwards (purple) and in females mainly during 
embryonic stages, approximately from 14.5 to 19.5 days post-coitum (dpc) (green). 
Specifically, RingoA/Spy1 is highly expressed in prophase I of meiosis. During this stage, 
telomeres attach to the nuclear envelope at pre-leptotene, chromosome synapsis starts at 
zygotene and concludes at pachytene, when meiotic recombination occurs. RingoA/Spy1 
expression starts at pre-leptotene and is not detectable as cells enter the diplotene stage (red 
line). (B) RingoA/Spy1 localizes at telomeres during prophase I of meiosis. RingoA/Spy1 
knockout mice are sterile and their gametocytes arrest at a pachytene-like stage showing 
impaired tethering of telomeres to the nuclear envelope, unrepaired double-strand breaks 
(DSB), telomere fusions, and non-homologous chromosome pairing.  
 
